Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim R Cressey

Showing results (71-80 of 166) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|July 14, 2010
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyTim R Cressey, Gonzague Jourdain, Boonsong Rawangban, et al.
Journal of the Pediatric Infectious Diseases Society|May 21, 2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young AdultsKajal B Larson, Tim R Cressey, Ram Yogev, et al.
Journal of the Pediatric Infectious Diseases Society|April 23, 2016
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young AdultsTim R Cressey, Ram Yogev, Andrew Wiznia, et al.
Plos One|May 17, 2019
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected childrenNontiya Homkham, Tim R Cressey, Naim Bouazza, et al.
Pharmaceutics|October 26, 2024
Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP ImmunochemotherapyTeerachat Punnachet, Tim R Cressey, Porntipa Apiwatnakorn, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
AIDS (London, England)|September 16, 2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in ThailandMarc Lallemant, Sophie Le Coeur, Wasna Sirirungsi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2015
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentTim R Cressey, Anchalee Avihingsanon, Guttiga Halue, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 8, 2015
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected WomenAlice Stek, Brookie M Best, Jiajia Wang, et al.
Pageof 17

Showing results (71-80 of 166) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|July 14, 2010
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyTim R Cressey, Gonzague Jourdain, Boonsong Rawangban, et al.
Journal of the Pediatric Infectious Diseases Society|May 21, 2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young AdultsKajal B Larson, Tim R Cressey, Ram Yogev, et al.
Journal of the Pediatric Infectious Diseases Society|April 23, 2016
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young AdultsTim R Cressey, Ram Yogev, Andrew Wiznia, et al.
Plos One|May 17, 2019
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected childrenNontiya Homkham, Tim R Cressey, Naim Bouazza, et al.
Pharmaceutics|October 26, 2024
Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP ImmunochemotherapyTeerachat Punnachet, Tim R Cressey, Porntipa Apiwatnakorn, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
AIDS (London, England)|September 16, 2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in ThailandMarc Lallemant, Sophie Le Coeur, Wasna Sirirungsi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2015
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentTim R Cressey, Anchalee Avihingsanon, Guttiga Halue, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 8, 2015
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected WomenAlice Stek, Brookie M Best, Jiajia Wang, et al.
Pageof 17